HYBN: Hybridon, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HYBN: Hybridon, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gulo who wrote (21)	3/19/2004 1:07:39 PM
From: Gulo	of 28

Other developments in the antisense field: March 10/04 AVI Biopharma proves that an oral antisense drug can be biologically active: biz.yahoo.com Feb 6/04 Genta Corp files NDA for the first antisense cancer co-treatment. FDA grants priority review status for action by June 8: genta.com ISIS brought first antisense drug to market in 1998: isispharm.com ISIS also has a number of candidates in clinical trials: isispharm.com Oncogenex raised $11.5M in a private placement last September to further clinical work on two of ISIS's candidates: oncogenex.ca It looks like the antisense field will get some press this year. -g

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next